colon
Conditions
Interventions
Test group:The first dose should be taken from 18:00 to 20:00 the night before the colonoscopy. The specific method is as follows:
(1) Pour a bottle of magnesium sulfate sodium potassium oral concent
Control group :1, the night before the examination, two hours after dinner, take 2 boxes of Sutaiqing, each box of Sutaiqing with 750ml plain water, taken within 1 hour.
2, On the day of the examinat
Sponsors
Department of Digestive Oncology, Civil Aviation General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1: Patients between 18 and 70 years old who are planned to receive treatment under colonoscopy, regardless of gender 2: Willing to sign a written informed consent, including agreeing to participate in the screening procedures to determine eligibility 3: Able to communicate effectively with the researcher and comply with the protocol requirements 4: take the bowel-cleansing medication correctly according to the study requirements
Exclusion criteria
Exclusion criteria: 1: A history of acute myocardial infarction (within 6 months), severe cardiovascular, hepatic or renal dysfunction, or mental disorders. 2: Taking anticoagulant drugs such as aspirin or warfarin, or having coagulation dysfunction 3: Patients taking or previously taking liraglutide, or known to have an allergy to liraglutide 4: Participants who are pregnant or planning to become pregnant during the study period 5: Patients with inflammatory bowel disease, chronic diarrhea, severe gastroparesis or intestinal obstruction 6: Currently participating in other clinical observation trials or participated in other clinical trials within 60 days
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The Boston Bowel; | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of intestinal bubble under colonoscopy;Defecation frequency;Cecal intubation rate;Ready-Interval between colorectal exams;time of operation ;Detection rate of adenoma and polyp;Sleep quality;Patient tolerance;Incidence of drug-related complications;Surgery-related incidence; | — |
Countries
China
Contacts
Public ContactJianping Cheng
Civil Aviation General Hospital
Outcome results
None listed